Home > Press > Mirkin Wins First NIH Director's Pioneer Award
Chad A. Mirkin, Ph.D., has been selected as one of the first recipients of the National Institutes of Health (NIH) Director's Pioneer Award.
Nanosphere Inc. Founder, Chad A. Mirkin, Ph.D., Wins First NIH Director's Pioneer Award
Northbrook, Ill., October 5, 2004
Nanosphere Inc., a
nanotechnology-based life sciences company, today announced its
founder, Chad A. Mirkin, Ph.D., has been selected as one of the first
recipients of the National Institutes of Health (NIH) Director's
Pioneer Award. The $2.5 million that Dr. Mirkin will receive is
designed to support highly innovative ideas and approaches to
critically important scientific questions. Dr. Mirkin is one of only
nine researchers chosen from a field of 1,350 nominees.
"This award recognizes the significant contributions of Dr.
Mirkin's nanotechnology research to the life sciences and their
potential to improve medical care," said William Moffitt, Nanosphere's
Chief Executive Officer.
Dr. Mirkin will use this new award to test far-ranging ideas with
the potential to make extraordinary contributions to medical research
including further exploration of breakthrough applications for his
ultra-sensitive protein detection technology first reported in the
September 2003 issue of Science.
The ability to study biological behavior at the cellular level
with nanotechnology tools is unprecedented. Ultra-sensitive protein
detection will enable the discovery and validation of new biomarkers
with up to one million times more sensitivity than current methods.
This level of sensitivity can lead to broader and earlier diagnosis of
illnesses from cancer to Alzheimer's disease.
This method for biomarker detection at extremely low
concentrations has been exclusively licensed to Nanosphere. Moreover,
new inventions arising from Dr. Mirkin's work in the field of
nanoparticles are licensed exclusively to Nanosphere for
commercialization in the field of diagnostics and life sciences.
Nanosphere, a privately held company with headquarters in
Northbrook, Illinois, is developing and commercializing nanotechnology
platforms that set new standards in patient care and public safety.
Nanosphere's technology enables the discovery of new biomarkers at
concentrations previously undetectable through traditional means while
addressing the persistent need for simplified molecular testing for
DNA, RNA and proteins.
Copyright © Nanosphere
If you have a comment, please
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
National Institutes of Health
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
The taming of magnetic vortices: Unified theory for skyrmion-materials March 3rd, 2015
Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015
Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015
Black phosphorus is new 'wonder material' for improving optical communication March 3rd, 2015